Subscribe to
our newsletters

Subscribe to our newsletters!

Subscribe to our newsletter and get the latest news from the Nordics straight to your inbox.

Search in Nordic Life Science Insight

-
April 26, 2018
InDex Pharmaceuticals

Notice of Annual General Meeting in InDex Pharmaceuticals Holding AB (publ)

Shareholders in InDex Pharmaceuticals Holding AB, reg. nr 559067-6820, are hereby summoned to the Annual General Meeting on May 24, 2018 at 5:00 p.m. (CET) at the company´s premises, Tomtebodavägen 23a in Stockholm, Sweden. Registration for the meeting begins at 4:30 p.m.

Notice of Annual General Meeting in InDex Pharmaceuticals Holding AB (publ)

Shareholders in InDex Pharmaceuticals Holding AB, reg. nr 559067-6820, are hereby summoned to the Annual General Meeting on May 24, 2018 at 5:00 p.m. (CET) at the company´s premises, Tomtebodavägen 23a in Stockholm, Sweden. Registration for the meeting begins at 4:30 p.m.

April 23, 2018 – Shareholders in InDex Pharmaceuticals Holding AB, reg. nr 559067-6820, are hereby summoned to the Annual General Meeting on May 24, 2018 at 5:00 p.m. (CET) at the company´s premises, Tomtebodavägen 23a in Stockholm, Sweden. Registration for the meeting begins at 4:30 p.m.

Shareholders who wish to attend the Annual General Meeting must be recorded in the share register maintained by Euroclear Sweden AB on May 18, 2018, and give notice of attendance to the company by e-mail to annika.lindmark@indexpharma.com or under address: InDex Pharmaceuticals Holding AB, Tomtebodavägen 23a, 171 77 Stockholm, no later than May 18, 2018.

The full notice of the Annual General Meeting (in the Swedish language) is available on the company’s website, www.indexpharma.com.

For more information:
Peter Zerhouni,
CEO
Phone: +46 8 508 847 35
E-mail: peter.zerhouni@indexpharma.com

InDex Pharmaceuticals in brief

InDex is a pharmaceutical development company focusing on immunological diseases where there is a high unmet medical need for new treatment options. The company’s foremost asset is the drug candidate cobitolimod, which is in late stage clinical development for the treatment of moderate to severe active ulcerative colitis – a debilitating, chronic inflammation of the large intestine. InDex has also developed a platform of patent protected discovery stage substances, so called DNA based ImmunoModulatory Sequences (DIMS), with the potential to be used in treatment of various immunological diseases.

InDex is based in Stockholm, Sweden. The company’s shares are traded on Nasdaq First North Stockholm. Redeye AB is the company’s Certified Adviser. For more information, please visit www.indexpharma.com 

Publication

This information is information that InDex Pharmaceuticals Holding AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation and/or the Swedish Financial Instruments Trading Act. The information was submitted for publication through the agency of the contact person set out above at 11:30 CET on April 23, 2018.

Documents

Last updated:
April 26, 2018

InDex Pharmaceuticals

InDex Pharmaceuticals lead drug candidate is cobitolimod – a new type of drug that can help patients back to a normal life. InDex has also developed a platform of patent protected substances, so called DNA based ImmunoModulatory Sequences (DIMS), with the potential to be used in treatment of various immunological diseases.

Click here to read more about us!
Get in touch with us!
Visit us

InDex Pharmaceuticals Holding AB (publ)
Tomtebodavägen 23a
SE-171 77 Stockholm, Sweden

Send us mail

April 23, 2018 – Shareholders in InDex Pharmaceuticals Holding AB, reg. nr 559067-6820, are hereby summoned to the Annual General Meeting on May 24, 2018 at 5:00 p.m. (CET) at the company´s premises, Tomtebodavägen 23a in Stockholm, Sweden. Registration for the meeting begins at 4:30 p.m.

Shareholders who wish to attend the Annual General Meeting must be recorded in the share register maintained by Euroclear Sweden AB on May 18, 2018, and give notice of attendance to the company by e-mail to annika.lindmark@indexpharma.com or under address: InDex Pharmaceuticals Holding AB, Tomtebodavägen 23a, 171 77 Stockholm, no later than May 18, 2018.

The full notice of the Annual General Meeting (in the Swedish language) is available on the company’s website, www.indexpharma.com.

For more information:
Peter Zerhouni,
CEO
Phone: +46 8 508 847 35
E-mail: peter.zerhouni@indexpharma.com

InDex Pharmaceuticals in brief

InDex is a pharmaceutical development company focusing on immunological diseases where there is a high unmet medical need for new treatment options. The company’s foremost asset is the drug candidate cobitolimod, which is in late stage clinical development for the treatment of moderate to severe active ulcerative colitis – a debilitating, chronic inflammation of the large intestine. InDex has also developed a platform of patent protected discovery stage substances, so called DNA based ImmunoModulatory Sequences (DIMS), with the potential to be used in treatment of various immunological diseases.

InDex is based in Stockholm, Sweden. The company’s shares are traded on Nasdaq First North Stockholm. Redeye AB is the company’s Certified Adviser. For more information, please visit www.indexpharma.com 

Publication

This information is information that InDex Pharmaceuticals Holding AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation and/or the Swedish Financial Instruments Trading Act. The information was submitted for publication through the agency of the contact person set out above at 11:30 CET on April 23, 2018.

Documents

Last updated:
April 26, 2018

InDex Pharmaceuticals

InDex Pharmaceuticals lead drug candidate is cobitolimod – a new type of drug that can help patients back to a normal life. InDex has also developed a platform of patent protected substances, so called DNA based ImmunoModulatory Sequences (DIMS), with the potential to be used in treatment of various immunological diseases.

Click here to read more about us!
Get in touch with us!
Visit us

InDex Pharmaceuticals Holding AB (publ)
Tomtebodavägen 23a
SE-171 77 Stockholm, Sweden

Send us mail